Remedy Robotics raises $62M for robotic, remote stroke thrombectomy
Image: Remedy Robotics / company website · press-kit
The San Francisco company raised a $62M Series B led by DCVC to fund a pivotal trial of its N1 System, which is not yet approved.
San Francisco's Remedy Robotics announced a $62 million Series B on 16 November 2026, led by returning investor DCVC. New investors include UC Investments, Skip Capital and the Australian pension fund Hostplus, joined by returning backers Build Collective, Blackbird, Divergent Capital and KdT Ventures.
The company is building the N1 System, a robot that steers catheters through blood vessels to treat stroke, with the aim that a neurosurgeon can operate remotely. The money funds a planned pivotal neurovascular trial with the University of California network, more prototype N1 deployments with partners such as SVIN Mission Thrombectomy and the Australian Stroke Alliance, and autonomous robotic software.
The trial is planned, not under way, and the article gives no start date or enrolment. The N1 System is a prototype deployed with partners and is not FDA-approved; Remedy says it is pursuing approval.
